1	Title: Prevalence of SARS-CoV-2 among high-risk populations in Lomé
2	(Togo) in 2020.

3

4 Authors:

5	Wemboo Afiwa HALATOKO ^{1¶} , Yao Rodion KONU ^{2,3¶*} , Fifonsi Adjidossi GBEASOR-
6	KOMLANVI ^{2,3} , Arnold Junior SADIO ^{2,3} , Martin Kouame TCHANKONI ³ , Koffi
7	Segbeaya KOMLANVI ³ , Mounerou SALOU ^{4,5,6} , Ameyo Monique DORKENOO ^{5,7} ,
8	Issaka MAMAN ¹ , Amétépé AGBOBLI ⁵ , Majesté Ihou WATEBA ^{5,6} , Komi Séraphin
9	ADJOH ^{5,6} , Edem GOEH AKUE ^{5,6} , Yem-bla KAO ⁶ , Innocent KPETO ⁶ , Paul PANA ⁶ ,
10	Rebecca KINDE-SOSSOU ⁷ , Agbeko TAMEKLOE ⁷ , Josée NAYO-APETSIANYI ⁷ ,
11	Simon-Pierre Hamadi ASSANE ⁷ , Mireille PRINCE-DAVID ^{4,5} , Sossinou Marcel
12	AWOUSSI ^{7,8} , Mohaman DJIBRIL ^{5,8} , Moustafa MIJIYAWA ^{5,7} , Anoumou Claver
13	DAGNRA ^{4,5,6,7&} , Didier Koumavi EKOUEVI ^{2,3, 6,9&}
14	
15 16 17 18 19 20 21 22 23 24 25 26 27	 Institut National d'Hygiène (INH), Lomé, Togo Université de Lomé, Département de Santé Publique, Lomé, Togo Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo Université de Lomé, Laboratoire de Biologie Moléculaire et d'Immunologie (BIOLIM), Lomé Togo Université de Lomé, Faculté des Sciences de la Santé, Lomé, Togo Conseil Scientifique pour la Riposte contre la Covid-19, Lomé, Togo Ministère de la Santé et de l'Hygiène Publique, Lomé, Togo Coordination Nationale de la Lutte contre la Covid-19, Lomé, Togo Centre Inserm, 1219, Institut de Santé Publique et de Développement et Université de Bordeaux, Bordeaux, France
28	* Corresponding author
29 30	Mail : <u>rodionko@yahoo.fr</u> (YRK)
31	[¶] Contributed equally to this work and share primary authorship
32	^{&} Contributed equally to this work and share senior authorship

33

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 Authors details

35	• WAH: <u>hjacky78@yahoo.fr</u>
36	YRK: <u>rodionko@yahoo.fr</u>
37	FAGK: <u>fifonsi.gbeasor@gmail.com</u>
38	AJS: <u>sadioarnorld@gmail.com</u>
39	MKT: <u>tchankonimartin@yahoo.fr</u>
40	KSK: <u>komlanvikoffi@yahoo.fr</u>
41	MS: mounerous@gmail.com
42	AMD: monicadork@yahoo.fr
43	IM: <u>mamanissaka@yahoo.fr</u>
44	AA: mag1.tg@gmail.com
45	MIW: majeste7@yahoo.fr
46	KSA: <u>komiadjoh@yahoo.fr</u>
47	• EGA: edemcardiol@yahoo.fr
48	YK: <u>yemblak@gmail.com</u>
49	 IK: <u>ikpeto@gmail.com</u>
50	PP: assimawepaul@gmail.com
51	RKS: <u>kinderebecca@yahoo.fr</u>
52	AT: <u>stanrameklo@yahoo.fr</u>
53	 JNA: <u>jyda45@hotmail.com</u>
54	SHA: simpassane@yahoo.fr
55	MPD: <u>mireilleprincedavid@gmail.com</u>
56	• SMA: awoussi@yahoo.com
57	MD: <u>m_djibril2000@yahoo.fr</u>
58	MM: moustafa.mijiyawa@gouv.tg
59	ACD: <u>claverdagnra@gmail.com</u>
60	DKE: <u>didier.ekouevi@gmail.com</u>
61	

63 Summary

Objective: This survey aims at estimating the prevalence of SARS-CoV-2 in high risk
 populations in Lomé.

Methods: From April 23rd to May 8th 2020, we recruited a random sample of participants from five sectors: healthcare, air transport, police, road transport and informal. We collected oropharyngeal swab for direct detection through real time reverse transcription polymerase chain reaction (rRT-PCR), and blood for antibodies detection by serological tests. The overall prevalence (current and past) of infection was defined by positivity for both tests.

Results: A total of 955 participants with a median age of 36 (IQR 32–43) were included and 71.6% (n=684) were men. Around 22.1% (n=212) were from the air transport sector, 20.5% (n=196) in the police, and 38.7% (n=370) in the health sector. Seven participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR at the time of recruitment and nine (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG against SARS-CoV-2. We found an overall prevalence of 1.6% (n=15), 95% CI: 0.9-2.6%.

79 Conclusion: The prevalence of the SARS-CoV-2 infection among high-risk 80 populations in Lomé was relatively low and could be explained by the various 81 measures taken by the Togolese government. Therefore, we recommend targeted 82 screening.

Keywords: Prevalence, SARS-CoV-2, Covid-19, high-risk populations, rRT-PCR,
serology, Togo.

85 Introduction

In December 2019, an outbreak of pneumonia (Covid-19) due to a new coronavirus first named 2019-nCoV, now officially SARS-CoV-2, occurred in China [1]. In less than five months, this outbreak had spread rapidly to every continent (except Antarctica) with more than 3.7 million people infected and more than 257,000 deaths recorded as of May 8th 2020 in 214 countries and territories [2]. In Africa, 32,953 (0.9%) cases of Covid-19 had been reported as of May 8th 2020 [3].

92

Since the beginning of the outbreak, health systems in developed countries have faced 93 many challenges to fight the Covid-19. Numerous assumptions have been made about 94 the true magnitude and evolution of the epidemic around the world. It has been 95 commonly assumed that officially reported data are underestimated [4,5], especially in 96 Africa. Insufficient diagnostic capacity of countries and the high proportion of 97 asymptomatic cases may explain such underestimation [6]. Thus, the World Health 98 Organization (WHO) has recommended a mass screening strategy for all countries 99 burdened by the epidemic with the hypothesis that [7] more tests performed would 100 result in an easier tracking of the spread of the virus and thus a decrease in 101 transmission [8]. However, there is insufficient testing capacity in many countries due 102 to a high global demand for antibody test kits [8] and GeneXpert which has recently 103 been validated by the US Food and Drug Administration [9]. To date, real-time reverse 104 transcription-polymerase chain reaction (rRT-PCR) remains the gold standard test for 105 the diagnosis of Covid-19. Antibodies are the best biomarkers to estimate the number 106 of people previously infected: its use could help estimate the prevalence and inform 107 testing strategies in populations at higher risk of Covid-19. 108

In Togo, the first case of Covid-19 was reported on March 5th 2020 and as of April 26th 110 111 2020, 98 cases were confirmed, including 6 deaths [10]. Only suspect cases, contacts, and travellers were being screened for SARS-CoV-2. The value of population mass 112 screening was debated considering the country's relatively limited diagnostic 113 capabilities. Few studies so far have been conducted to estimate the prevalence of 114 SARS-CoV-2 based on rRT-PCR test or antibody test including studies in Iceland [11], 115 116 Santa-Clara County in USA [12] and Switzerland [13]. To our knowledge, there is no data available on the prevalence of SARS-CoV-2 in Sub-Saharan Africa. Based on the 117 low incidence of SARS-CoV-2 infection observed in the general population, the Swiss 118 119 National Covid-19 Science Task Force recommends focusing research at the population level on subpopulations at higher risk of infection [14]. Therefore, we 120 conducted a pilot survey in high risk populations to estimate the prevalence of SARS-121 CoV-2 using a rRT-PCR test in order to refine screening strategies in the fight against 122 the pandemic in Togo. 123

124

126 Methods

127 Study design and sampling

A cross-sectional study was conducted by a multi-disciplinary team (demographers, 128 epidemiologists, biologists, biostatisticians) among high-risk populations in Lomé 129 (capital city of Togo) from April 23rd to May 8th, 2020. Participants were recruited from 130 five professional sectors: healthcare (doctors, nurses, pharmacy auxiliaries, hospital 131 132 administrators), air transport, police, road transport (taxi and moto-taxi drivers) and informal (market sellers and craftsmen). These groups were targeted because they are 133 134 at high risk of contamination during epidemics for their high probability of being in close contact with travelers or with Covid-19 patients [15,16]. Participants were eligible to 135 participate in the study if the following four criteria were fulfilled: (i) \geq 18 years of age; 136 (ii) working in one of the five sectors; (iii) having been regularly present at the 137 workstation for the past 30 days; (iv) living in Lomé for the past 3 months. 138

Several sampling methods were used for participants' selection based on the expected 139 total size of the target population and the availability of a sampling frame. First, 140 exhaustive recruitment was performed among the police (road safety officers) and 141 142 people in air transport (International Airport Gnassingbe Eyadema, Lomé, Togo). Second, participants from the informal sector were recruited based on an open 143 invitation. Third, random sampling (two or three stage) was performed for the 144 recruitment of taxi motos (road transport) and health care workers. For example, for 145 the selection of taxi moto drivers we performed a two-stage sampling with the selection 146 of the company, then the selection of the drivers working in the company. 147

148

149

150 Sample size estimation

The sample size was estimated using a single proportion population formula with a 95% confidence level, 1% margin of error, and 2% estimated prevalence of SARS-CoV-2 among high risk populations (as defined above) based on surveillance data in travelers in Togo (Ministry of health). A 10% unusable biological specimens or nonresponse rate was anticipated and the minimum number of participants was estimated at 837.

157 Data collection

158 We established a test site at the 'Faculté des Sciences de la Santé de l'Université de Lomé' (Faculty of medicine, University of Lomé) and invited the target population to 159 join us on site for inclusion. After eligibility screening and written informed consent 160 approval, sociodemographic characteristics and Covid-19 epidemiological data were 161 collected using a standardized questionnaire. The questionnaire was administered by 162 163 a trained study team (medical doctors) during a face-to-face interview. Oropharyngeal (OP) and blood samples were collected by trained and well-equipped staff of the 164 'Institut National d'Hygiène' (INH) which is the reference laboratory for SARS-CoV-2 165 testing in Togo. Oropharyngeal swabs were collected using Eswab type swabs and 166 samples were tested for SARS-CoV-2 using rRT-PCR at the INH. Whole blood 167 specimens were collected in EDTA tubes to test for anti-SARS-CoV-2 serologic 168 markers at the 'Laboratoire de Biologie Moléculaire et d'Immunologie, Université de 169 Lomé' (BIOLIM). 170

171

172

174 Laboratory procedures

175 Molecular detection of SARS-CoV-2 using TIB MOL BIOL rt RT-PCR Kit

176 Detection of SARS-CoV-2 in oropharyngeal samples has been performed using 177 molecular biology methods, such as recommended by WHO and US CDC [17,18].

The TIB MOLBIOL (Olfert Landt, Berlin Germany) LightMix® SarbecoV E-gene plus 178 EAV control PCR kit and the LightMix® Modular COVID-19 RdRPgene has been used 179 for the amplification and qualitative detection of nucleic acid of SARS-CoV-2. 180 Amplification was carried out after viral RNA extraction using the QIAamp Viral RNA 181 182 Mini Kit (Qiagen Str, Hilden, Germany). The detection algorithm used was a two-step process involving first a screening assay for sarbecovirus by targeting the E gene to 183 detect both SARS virus and COVID-19 virus; and secondly a confirmation assay for 184 COVID-19 virus only by targeting the RNA dependent RNA polymerase gene (RdRp), 185 specific gene for SARS-CoV-2. 186

187 Internal guality control was ensured by the use of three controls included in the kit supplied by the company TIB MOL BIOL (Eresburgstr. 22-23 | D-12103 Berlin, 188 Germany). A control during extraction (EAV extraction control, ref. 40-0776-96, TIB 189 MOL BIOL, Germany) to detect possible inhibition of PCR; a positive control for each 190 gene to be detected (positive control of the E gene, ref. 40-0776-96, TIB MOL BIOL, 191 Germany and positive control of the RdRp gene; ref. 53-0777-96, TIB MOL BIOL, 192 Germany) to ensure good performance of the PCR reaction and a negative control (no 193 control model, NTC) to verify the absence of contamination of the reagents. The 194 195 performance of the test is only accepted if the values of the threshold cycles (Ct) of the positive controls (PTC) of E positive gene control <30; Positive control of RdRp gene 196

<30; Control of the extraction of the EAV <33 and the NTC does not generate any
 amplification curve.

A sample was considered positive if the Ct genes of E <36 and RdRp <40 with the presence or absence of EAV extraction control. If the RdRp gene did not appear or the Ct> 40, the sample was considered probable at Covid-19. A sample was considered negative (below the threshold) if no amplification curve was observed for the E and RdRp genes and the EAV extraction control <33. If, on the other hand, the EAV had no curve, the test was retaliated for the corresponding sample.

The INH molecular biology laboratory participated in May 2020 in the external quality control under the supervision of WHO within the framework of its pilot program external quality assessment program (EQAP) for the detection of SARS-CoV-2 virus by RT-PCR.

209 Detection of SARS-CoV-2 antibodies

Detection of serological markers (Immunogobulins G and M) of SARS-CoV-2 infection
was carried out at BIOLIM using the Lungene® Rapid Test (Hangzhou Clongene
Biotech Co, Ltd). The sensitivity and specificity were 72.85% and 85.02%, respectively
[19].

This test was also validated by Laboratory Department of the ministry of health in Togo. Sensitivity of the assay using samples from participants previously diagnosed with Covid-19 at the day of hospitalization was 77.1% for IgM or IgG and specificity of 95.4%. Moreover, the sensitivity was measured 7 days after hospitalization and reported a sensitivity of 93.3% for IgG signing the contact with SARS-CoV-2 [20].

219

220 Care and treatment

Biological samples tests results were available within 48 hours. All participants screened positive for SARS-CoV-2 were quarantined in a dedicated hotel or at the national Covid-19 treatment center and those who were tested negative were invited to respect all the mitigation measures proposed by the government.

225

226 Statistical analysis

Descriptive statistics were performed and results are presented with frequency 227 228 tabulations and percentages for categorical variables. Quantitative variables are presented as medians with their interguartile range (IQR). Seroprevalence of 229 antibodies against SARS-CoV-2, prevalence of SARS-CoV-2 infection by rRT-PCR 230 and overall prevalence of past or current infection (positive rRT-PCR or antibody 231 seropositivity) were estimated with their 95% confidence interval (95%CI). 232 233 Comparisons of categorical variables were performed using chi-square or Fisher's exact tests. Data analyses were performed using R[©] version 3.4.3 software and the 234 level of significance was set at 5%. 235

236

237 Ethical considerations

Ethical approval was obtained from the 'Comité de Bioéthique de Recherche en Santé' (Bioethics Committee for Health Research) from the Togo Ministry of Health (No. 004/2020/CBRS). Potential participants were informed about the study purpose and procedures, potential risks and protections. Those willing to participate were invited to sign a consent prior to participation.

243 **Results**

244 Sociodemographic characteristics

245	A total of 955 people with a median age of 36 (IQR 32-43) were included in the study
246	and 71.6% (n=684) were men. Approximately 22.1% (n=212) were in the field of air
247	transport, 20.5% (n=196) in the police, 5.8% (n=55) in the informal sector, 38.7%
248	(n=370) in the health sector and 12.8% (n=122) in the road transport sector. None of
249	the participants had been previously diagnosed Covid-19 positive or hospitalized in the
250	last 30 days before the enrolment. The majority of participants, (n=936, 98.0%) were
251	Togolese, around two-thirds (n=636, 66.6%) were in a couple and half (n=487, 51.0%)
252	of them had university level degree. The sociodemographic characteristics according
253	to the sector of activity are summarized in Table 1.
254	
255	Table 1.
256	
257	Participants came from all the five health districts of the city of Lomé as shown in Figure
258	1.
259	Figure 1
260	
261	Prevalence of current infection as determined by a positive rRT-PCR
262	Seven participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR of SARS-CoV-2
263	at the time of recruitment and the prevalence varied from 0% for the participants from
264	the road transport to 1.8% for those in the informal sector of activities. The prevalence
265	was 0.7%, 95% CI [0.3-1.8] in men and 0,7%, 95% CI [0.1-2.8] in women (p=0.683).
266	
267	

268	Seroprevalence of antibodies against SARS-CoV-2
269	Nine participants (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG against
270	SARS-CoV-2 (Table 2 and Figure 2) and one of them was seropositive for both IgM
271	and IgG. Table 2 summarize the seroprevalence of IgG or IgM according to the sector
272	of activities. Thus, a total of 15 participants (1.6%, 95% CI: 0.9-2.6%) were positive for
273	rRT-PCR or seropositive for IgM or IgG against SARS-CoV-2. This prevalence ranged
274	between 0.8% in the road transport sector and 1.9% in the health sector (Table 2).
275	
276	Table 2 and Figure 2
277	
278	Clinical manifestations, care and treatment
279	Six out of seven rRT-PCR positive participants were asymptomatic. The symptomatic
280	participant had presented fever, headaches, and myalgia during the two weeks prior
281	to enrolment. All rRT-PCR positive participants were hospitalized at the national
282	reference center for Covid-19 and treated with hydroxychloroquine and azithromycin
283	as recommended by the national guidelines [21]. Description of the seven rRT-PCR
284	positive participants is presented in Table 3.
285	
286	Table 3
287	
288	

289 **Discussion**

To our knowledge, this is the first study reporting the prevalence of SARS-CoV-2 in 290 sub-Saharan-Africa in a representative sample of high-risk populations. The present 291 study was conducted in a context of urgent need for data for decision-making and 292 refinement of response strategies. SARS-CoV-2 prevalence was assessed by 293 294 molecular biology and serologic tests. In Lomé, capital city of Togo, 2 months after the first case of Covid-19, the prevalence of SARS-CoV-2 infection among persons at high 295 risk for infection was 1.6% based on the presence of antibodies and viral genomes. 296 Using rRT-PCR alone, only 0.7% of the study population was found to be infected with 297 SARS-CoV-2. 298

299

Few studies have focused on high risk populations for Covid-19. In the United States, 300 a screening of an alleged high-risk population of residents and staff members from five 301 homeless shelters was conducted in the cities of Boston, San Francisco, Seattle and 302 Atlanta [22]. This study reported a prevalence of SARS-CoV-2 infection ranging from 303 4 to 66% among residents and 1 to 30% among staff [22]. Healthcare workers (HCWs) 304 are particularly considered as high-risk populations. In a study conducted in United 305 306 Kingdom (UK), over a 3-week period (April 2020), 1,032 asymptomatic HCWs were screened for SARS-CoV-2 in a large UK teaching hospital. rRT-PCR was used to 307 detect viral RNA from a throat and nose self-swab [23]. Among these asymptomatic 308 HCWs, 3% were tested positive for SARS-CoV-2 [23]. In Lomé, the prevalence among 309 HCWs was 0.5% based on virological test and 1.9% (virological and antibody test), but 310 this included administrative and pharmacy staff. 311

312

Most Covid-19 prevalence surveys have been carried out in the general population. In 313 314 a survey conducted in Iceland, 1.221 (13.3%) of the 9,199 people who were recruited using the symptom-targeted method were positive for SARS-CoV-2 infection [11]. 315 Among those tested by open invitation selection or random selection, SARS-CoV-2 316 prevalence was 0.8% and 0.6%, respectively [11]. In another survey in Santa Clara 317 County, California, USA, the crude prevalence of SARS-CoV-2 antibodies was 1.5% 318 [12]. After weighing for population demographics of Santa Clara County, the 319 prevalence was 2.8% [12]. In Geneva, Switzerland, another study found that the 320 seroprevalence of SARS-CoV-2 in the general population was low (about 5%), despite 321 322 the high incidence of Covid-19 in Geneva compared with other cantons [13]. All of the studies carried out in the general population based on survey or mathematical model 323 such as in France (4.4%), reported low prevalence of SARV-CoV-2 despite the 324 magnitude of the infection [24]. 325

326

Recent evidence highlighted a highest sensitivity of the use of nasopharyngeal 327 samples compared to oropharyngeal ones in rRT-PCR [25]. In a study conducted in 328 329 China including 353 patients, using both oropharyngeal and nasopharyngeal swabs, 330 SARS-Cov-2 rRt-PCR was positive in 19.0% of nasopharyngeal specimens against 7.6% in oropharyngeal [26]. Another survey reported that the SARS-CoV-2 detection 331 rate was significantly higher for nasopharyngeal swabs [46.7% (56/120)] than 332 oropharyngeal swabs [10.0% (12/120)] (P < 0.001) [25]. This could certainly contribute 333 to underestimate the prevalence reported in our population. This prevalence could be 334 multiplied by two or three according to available data but remain less than 3%. 335 However, at the time of the survey there was no clear recommendation on which swab 336

to choose. Also, unavailability of nasopharyngeal swabs didn't allow us to collect bothspecimens.

339

The use of serological tests as an effective method for the detection of SARS-CoV-2 340 has been reported previously in the literature. In a study conducted in Wuhan, China, 341 of the 56 enrolled symptomatic patients, 40 (71%) showed negative nucleic acid tests 342 and 16 (29%) were positive. Among the 40 negative patients, 34 (85%) tested positive 343 for the presence of IgM antibodies. Among the 16 patients who tested positive with 344 nucleic acid tests, one patient showed a negative IgM level. The IgG antibody test was 345 346 positive in all 56 patients [27]. In the present study, the prevalence of SARS-CoV-2 increased to 1.6% when serology results were included in the analysis. Based on the 347 validation of the test in Togo and elsewhere, the data reported on serological samples 348 seem reliable. Since serology is rapid and inexpensive it could constitute an attractive 349 screening alternative for countries with limited resources in the context of easing of 350 restrictive measures. 351

352

This study targeted people considered at high risk for Covid-19 based on professional activity as recently recommended by the Swiss National Covid-19 Science Task Force. The WHO also recommends to conduct survey to estimate the prevalence of SARS-CoV-2 in the community, but also for critical population subgroups such as nursing homes or health care facilities [28].

358

This study had some limitations. First, the population included was not representative of the general Togolese population, we actively chose this selection criterion to have a high probability of identifying cases of SARS-CoV-2 infection. Second, we cannot

exclude selection bias in our sample due to the recruitment methods. Based on the low
prevalence, we did not study the association between prevalence of SARS-CoV-2
according to the different sectors. Finally, this study was conducted only in Lomé,
capital city of Togo, where 55% of cases of Covid-19 were identified at the time of the
survey.

367

368 **Conclusion**

In conclusion, the prevalence of the SARS-CoV-2 infection in the capital city among 369 high-risk populations was relatively low two months after the notification of the first 370 case. The low circulation of the virus in high-risk populations could be explained by the 371 various measures taken by the Togolese government. Based on this result, 372 generalized screening of SARS-CoV-2 would be time-consuming, not cost effective 373 and at a high risk of reagent rupture. Therefore, we recommend targeted approach for 374 screening. Targeted screening could include health professionals, airport staff; 375 376 teachers could also be considered in the event of schools' reopening. Repeated 377 prevalence surveys are needed to refine the strategies to fight against Covid-19 in Togo. 378

379

380

381

383 List of abbreviations

384 95% CI: 95% confidence interval; IQR: interquartile range

385 Acknowledgements

We are thankful to the participants who accepted to participate in this study and the medical students of the 'Faculté des Sciences de la Santé-Université de Lomé' who performed data collection for the study.

We hereby also acknowledge the work of the teams of the two laboratories involved in this study, the members of sectorial unit of management of pandemic in the 'Ministère de la Santé et de l'Hygiène Publique' (Ministry of Health), the rapid response teams of health region of Lomé, the staff of Santé Intégrée and the World Health Organization Representative in Togo.

Finally, we thank, Alexandra Bitty-Anderson, Abidjan, Côte d'Ivoire; El Houda Roukaya, Alex DeVille and Hannah Wang who edited the English version of this paper.

396

397 **Competing interests**

398 The authors declare that they have no competing interests.

399 Funding

This work was supported the Government of the Republic of Togo. Dr Rodion KONU was supported by the Agence Nationale de Recherche sur le sida et les hépatites virales (ANRS)' in France for his training in Masters of Public Health degree at the 'Université de Bordeaux' through the Françoise Barre Sinoussi Fellowship 2019.

404 **References**

- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J and al. China Novel Coronavirus Investigating
 and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl
- 407 J Med. 2020; 382(8):727-733. doi: 10.1056/NEJMoa2001017.
- 408 2. World Health Organization (WHO), Health Emergencies Programmes. Weekly update on
- 409 COVID-192 –8 May 2020 [Internet]. 2020 [Cited 14/07/2020]. Available from:
- 410 https://www.who.int/publications/m/item/weekly-update-on-covid-19---8-may-2020.
- 411 3. World Health Organization, Regional Office for Africa (OMS/AFRO). Covid 19 : Situation update
- 412 for the WHO African region, 5 May 2020 [Internet]. 2020 [Cited 14/07/2020]. Available from:
- 413 https://apps.who.int/iris/bitstream/handle/10665/331989/SITREP_COVID-
- 414 19_WHOAFRO_20200506-eng.pdf.
- 4. Richterich, Peter. Severe underestimation of COVID-19 case numbers: effect of epidemic growth
 rate and test restrictions. medRxiv. 2020; 10.1101/2020.04.13.20064220.
- 417 5. Lachmann A, Jagodnik KM, Giorgi FM, Ray F. Correcting under-reported COVID-19 case
- 418 numbers: estimating the true scale of the pandemic. medRxiv. 2020; 2020.03.14.20036178.
- 419 doi:10.1101/2020.03.14.20036178.
- Pan American Health Organization (PAHO), World Health Organization (WHO). Epidemiological
 Update Novel coronavirus (COVID-19). Washington, D.C.: PAHO/WHO; 2020, 8p.
- World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus
 Disease 2019 (COVID-19). Beijing : WHO ; 2020, 40p.
- 424 8. Elflein J. Rate of COVID-19 testing in most impacted countries worldwide as of May 11, 2020
 425 [Internet]. 2020 [Cited 13/04/2020]. Available from:
- 426 https://www.statista.com/statistics/1104645/covid19-testing-rate-select-countries-worldwide/.
- 427 9. US FooD and Drug Administration (FDA). Emergency Use Authorizations [Internet]. 2020 [Cited
- 428 16/05/2020]. Available from: https://www.fda.gov/medical-devices/emergency-situations-medical-
- 429 devices/emergency-use-authorizations#covid19ivd.

- 430 10. République Togolaise, Site d'information officiel du Gouvernement. Coronavirus au Togo :
- 431 Chiffres mis à jour [Intenret]. 2020 [Consulté le 27/04/2020]. Disponible sur :
- 432 https://covid19.gouv.tg/.
- 433 11. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL and al.
- 434 Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med. 2020: NEJMoa2006100. doi:
- 435 10.1056/NEJMoa2006100.
- 436 12. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R and al. COVID-19
- Antibody Seroprevalence in Santa Clara County, California. medRxiv 2020.04.14.20062463; doi:
 https://doi.org/10.1101/2020.04.14.20062463.
- 439 13. Hôpitaux Universitaires Genève (HUG). Séroprévalence COVID-19 : Première estimation de la
- 440 prévalence d'anticorps anti-SARS-CoV-2 IgG dans la population genevoise [Internet]. 2020
- 441 [consulté le 04/05/2020]. Disponible sur : https://www.hug-ge.ch/medias/communique-
- 442 presse/seroprevalence-covid-19-premiere-estimation.
- 14. National COVID-19 Science Task Force (NCS-TF). The role of serological testing in the COVID19 response in Switzerland. Berne : NCS-TF ; 2020, 8p.
- 445 15. Bernard SS, Rolland P, Silue Y, Mailles A, Campese C, Simondon A and al. First cases of
- 446 coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control
- 447 measures, January 2020. Euro Surveill. 2020; 25(6):2000094. doi: 10.2807/1560-
- 448 7917.ES.2020.25.6.2000094.
- 16. Government of Canada. Risk-informed decision-making for mass gatherings during COVID-19
- 450 pandemic [Internet]. 2020 [Cited at 04/03/2020]. Available from :
- 451 https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-
- 452 infection/health-professionals/mass-gatherings-risk-assesment.html.
- 453 17. World Health Organization (WHO). Laboratory testing for coronavirus disease 2019 (COVID-19)
- 454 in suspected human cases, Interim guidance 2 March 2020 [Internet]. 2020 [Cited 14/07/2020].
- 455 Available from: https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-
- 456 laboratory-2020.4-eng.pdf?sequence=1&isAllowed=y.

- 457 18. Centers for Disease Control and prevention (CDC). Interim Guidelines for Collecting, Handling,
- 458 and Testing Clinical Specimens for COVID-19 [Internet]. 2020 [Cited 14/07/2020]. Available
- 459 from: https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html.
- Vásárhelyi B, Kristóf K, Ostorházi E, Szabó D, Prohászka Z, Merkely B. The diagnostic value of
 rapid anti IgM and IgG detecting tests in the identification of patients with SARS CoV-2 virus
 infection. Orv Hetil. 2020; 161(20):807-812.
- 463 20. Centre National de référence pour le VIH, Laboratoire de virologie du CHU-SO. Evaluation du
- 464 test « CLUNGENE RAPID TEST ». In : Ministère togolais de la santé et de l'hygiène publique
- 465 (MSHP), Direction de la Pharmacie du Médicament et des Laboratoires (DPML). Rapport
- d'évaluation de la performance des tests de diagnostic sérologique de SARS-CoV-2 soumis au
- 467 ministère de la santé dans le cadre du processus d'homologation des DMDIV au Togo. Lomé:
- 468 DPML; 2020. Disponible sur : https://drive.google.com/file/d/1QqF_Wz-JVrdLREgfVnJ2pGGkkl7-
- 469 e-XY/view?usp=sharing.
- 470 21. République Togolaise, Ministère de la santé et de l'hygiène publique (MSHP). Protocole national
 471 de prise en charge des cas de COVID-19. Lomé : MSHP ; 2020, 15p.
- 472 22. Mosites E, Parker EM, Clarke KEN, Gaeta JM, Baggett TP, Imbert E and al. Assessment of
- 473 SARS-CoV-2 Infection Prevalence in Homeless Shelters Four U.S. Cities, March 27-April 15,

474 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(17):521-522.

- 475 23. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S and al. Screening of
- 476 healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19
- 477 transmission. medRxiv. 2020.05.09.20082909; doi:
- 478 https://doi.org/10.1101/2020.05.09.20082909.
- 479 24. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J and al. Estimating the
 480 burden of SARS-CoV-2 in France. Science. 2020. pii: eabc3517. doi: 10.1126/science.abc3517.
- 481 25. Wang H, Liu Q, Hu J, Zhou M, Yu MQ, Li KY et al. Nasopharyngeal Swabs Are More Sensitive
- 482 Than Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load.
- 483 Front Med (Lausanne). 2020;7:334.

- 484 26. Wang X, Tan L, Wang X, Liu W, Lu Y, Cheng L et al. Comparison of nasopharyngeal and
- 485 oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both
- 486 specimens simultaneously. Int J Infect Dis. 2020; 94:107-109.
- 487 27. Xie J, Ding C, Li J, Wang W, Guo H, Lu Z and al. Characteristics of patients with coronavirus
- 488 disease (COVID-19) confirmed using an IgM-IgG antibody test. J Med Virol. 2020;
- 489 https://doi.org/10.1002/jmv.25930.
- 490 28. World Health Organization (WHO). Population based age stratified seroepidemiological
- 491 investigation protocol for COVID-19 virus infection. Geneva: WHO; 2020, 15p.
- 492







Figure 1: Localization of the participants in the city of Lomé (Togo)



497



	Air transport	Police	Informal sector	Health sector	Road transport	Total
	n=212	n=196	n=55	n=370	n=122	N=955
Age (years)						
<36	90 (42.5)	121 (61.7)	17 (30.9)	158 (42.7)	48 (39.3)	434 (45.4)
≥36	122 (57.5)	75 (38.3)	38 (69.1)	212 (57.3)	74 (60.7)	521 (54.6)
Sex						
Men	179 (84.4)	168 (85.7)	34 (61.8)	181 (48.9)	122 (100.0)	684 (71.6)
Women	33 (15.6)	28 (14.3)	21 (38.2)	189 (51.1)	0 (0.0)	271 (28.4)
Nationality						
Togolese	205 (96.7)	196 (100.0)	52 (94.5)	364 (98.4)	119 (97.5)	936 (98.0)
Others	7 (3.3)	0 (0.0)	3 (5.5)	6 (1.6)	3 (2.5)	19 (2.0)
In couple						
No	49 (23.1)	49 (25.0)	10 (18.2)	169 (45.7)	42 (34.4)	319 (33.4)
Yes	163 (76.9)	147 (75.0)	45 (81.8)	201 (54.3)	80 (65.6)	636 (66.6)
Education level						
None	3 (1.4)	0 (0.0)	5 (9.1)	5 (1.4)	11 (9.0)	24 (2.5)
Primary	2 (0.9)	1 (0.5)	4 (7.3)	11 (3.0)	26 (21.3)	44 (4.6)
Secondary	105 (49.5)	143 (73.0)	15 (27.3)	69 (18.6)	68 (55.7)	400 (41.9)
University	102 (48.1)	52 (26.5)	31 (56.4)	285 (77.0)	17 (13.9)	487 (51.0)

502 Table 1: Sociodemographic characteristics according to sector of activity, Lomé, Togo

Table 2: Prevalence of SARS-Cov-2 according to sector of activity in Lomé, Togo

	Air transport	Police	Informal sector	Health sector	Road transport	Total	95%CI
	n=212	n=196	n=55	n=370	n=122	N=955	
rRT-PCR+	3 (1.4)	1 (0.5)	1 (1.8)	2 (0.5)	0 (0.0)	7 (0.7)	[0.3-1.6]
IgM+	1 (0.5)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.2)	[0.03-0.8]
lgG+	2 (0.9)	0 (0.0)	0 (0.0)	5 (1.4)	1 (0.8)	8 (0.8)	[0.4-1.7]
rRT-PCR+ or IgG+ or IgM+	4 (1.9)	2 (1.0)	1 (1.8)	7 (1.9)	1 (0.8)	15 (1.6)	[0.9-2.6]

+: Positive 95%CI: 95% Confidence interval

Table 3: Description of rRT-PCR positive participants (N = 7)

	Age (years)	Sex	Sector of activity	lgG +	lgM +	Covid-19 symptoms
Participant 1	58	Male	Air transport	No	No	No
Participant 2	52	Male	Air transport	No	No	No
Participant 3	35	Male	Air transport	Yes	No	No
Participant 4	37	Male	Health	No	No	No
Participant 5	30	Female	Health	No	No	Yes*
Participant 6	52	Male	Informal	No	No	No
Participant 7	32	Female	Police	No	No	No

*Presence of fever, headache and myalgia within the past two weeks before enrolment